Health Law Alliance is publishing this alert to inform pharmacies and providers of a significant enforcement trend that could have serious implications for your business operations. ESI has drastically increased the number of audits it conducts of telehealth relationships, including providers that have contractual relationships with a provider named EZScripts. If you are doing business with EZScripts or other telehealth platforms, you will be subject to increased scrutiny from ESI and other PBMs.
Claim Phishing Audits on the Rise
Telehealth platforms often use pharmacies' National Provider Identifier (NPI) number to run "test" claims, often referred to as benefits eligibility checks.
PBMs and other entities involved in the claims adjudication process, such as McKesson's RelayHealth "switch," typically use "terms and conditions" and other contractual provisions to prohibit these transmissions.
ESI is now attempting to recoup on claims that are associated with these eligibility checks, irrespective that the claims are reversed and not paid. Specifically, ESI is demanding that pharmacies repay the entire amount at issue, meaning the entire dollar value arising from both paid and test claims.
This situation is deeply concerning. ESI is not only reclaiming all reimbursements made to these pharmacies, but also seeking to recover the monetary value of test claims for which pharmacies were never reimbursed, placing the financial stability of numerous pharmacies in jeopardy.
We Defend You Against ESI
If your pharmacy has done business with telehealth platforms such as Noble or EZScripts, and you have received an audit notice from ESI, we strongly urge you to contact us immediately. Our experienced PBM audit attorneys will provide you with a free consultation to discuss your options and provide the legal guidance necessary to protect your pharmacy from potentially devastating financial repercussions. Schedule a free consultation now.
MORE ARTICLES BY CATEGORY
Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing
Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.
Read More >>9th Circuit’s Landmark EKRA Ruling—What Providers Should Know
On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.
Read More >>Collateral Consequences Mount Quickly After Adverse DEA Inspection
Adverse findings during a DEA inspection can trigger a chain reaction of serious consequences for pharmacies, including increasing fines, suspension or revocation of DEA registrations and pharmacy licenses, costly False Claims Act (FCA) lawsuits, and potential criminal liability.
Read More >>Heath Law Alliance Secures Reversal of a Medicaid Payment Suspension
Health Law Alliance successfully secured a full reversal of a Medi-Cal payment suspension for a California pharmacy, overturning speculative allegations made by the Department of Health Care Services. This case highlights the firm’s ability to protect healthcare providers against unjust enforcement actions and the critical value of experienced legal counsel in Medicaid and insurance disputes.
Read More >>
